Researchers from the Lambert Initiative for Cannabinoid Therapeutics and the Sydney Pharmacy School at the University of Sydney are surveying pharmacists to identify attitudes towards, experiences with and education level on prescription medicinal cannabis and low-dose CBD.
The Lambert Initiative team, led by pharmacist Zeeta Bawa, has launched the survey with support from the PSA and Sydney Pharmacy School at the University of Sydney.
“Pharmacists are a vital link in the access to medicinal cannabis products for the Australian community,” said Ms Bawa.
“We want to ensure their professional practice is supported in light of legislative changes affecting low-dose cannabidiol. This survey will form the basis on which tailored education and management strategies can be crafted.”
Cannabidiol (CBD) is a non-intoxicating component of the cannabis plant with evidence supporting its use in treating conditions such as epilepsy, anxiety, pain and insomnia.
CBD has been approved as a medicine to treat certain rare types of epilepsy in children at high doses. Recently, the Therapeutics Goods Administration allowed low-dose CBD containing products, (up to a maximum of 150 mg/day) to be supplied over-the-counter by a pharmacist, without a prescription.
While the sale of CBD products has been approved, no products have yet been registered for distribution in Australia.
Click here to read the full article from AJP, and be sure to complete the Your Guide to Cannabis-Based Medicine education module on iTherapeutics to better assist customers seeking medicinal cannabis.
Source: https://ajp.com.au/news/pharmacy-announcements/survey-are-you-ready-for-low-dose-cannabidiol-products/ , viewed 4 June 2021.